Abstract: A vessel has an interior surface facing a lumen. The interior surface includes a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer. The tie coating or layer can comprise SiOxCy or SiNxCy, where x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The barrier coating or layer can comprise SiOx, wherein x is from 1.5 to 2.9. The barrier coating or layer reduces the ingress of atmospheric gas into the lumen. The pH protective coating or layer can comprise SiOxCy or SiNxCy, as well. In an embodiment, in the presence of a fluid composition contained in the lumen and having a pH between 5 and 9, the calculated shelf life of the package can be more than six months at a storage temperature of 4° C.

Abstract: A needle-less vial assembly that includes a substance transfer assembly configured to telescopically engage with a vial neck of a vial. A first portion of the substance transfer assembly is configured to sealingly engage with an interior wall of the vial neck, where the first portion includes a first inlet configured to receive a substance from the vial. A second portion of the substance transfer assembly is configured to matingly engage with a syringe, and includes an outlet configured to dispense the substance to the syringe. A channel is defined through the first portion and the second portion, thereby enabling fluid communication of the substance from the vial to the syringe via the first inlet and the outlet.

Abstract: An intelligent pill box device comprising: a base and a display panel. The base includes a plurality of cylindrical shaped receptacles for storing medication bottles wherein each receptacle includes a radio frequency identification reader, a faraday cage, and a load cell at the bottom of the receptacle to measure the weight of the contents of the receptacle.

Abstract: A method of feeding breast milk to an infant includes providing a spout pouch having a spout, providing a plurality of adapters configured to couple to the spout pouch, coupling the spout of the spout pouch to a first adapter, coupling the first adapter to a breast pump, operating the breast pump to express breast milk into the spout pouch, so that the spout pouch collects the expressed breast milk, coupling a second adapter to the spout of the spout pouch, and coupling the second adapter to a nipple, so that expressed breast milk flows from the spout pouch to the nipple. Other systems, methods, and components are also provided.

Abstract: A mixture containing at least one first component A and at least one second component B, characterized in that said at least one first component A comprises a methyl methacrylate, a copolymer of methyl methacrylate dissolved in excess methyl methacrylate, optionally comprising, additionally dissolved therein, at least one polyfunctional (meth)acrylate, especially ethylene glycol dimethacrylate, butanediol dimethacrylate, hexanediol dimethacrylate, triethylene glycol dimethacrylate (TEGDMA), tetraethylene glycol dimethacrylate, diurethane dimeth-acrylate, bis(hydroxymethacryloyloxypropoxy)phenylpropane (bis-GMA), polyethylene glycol dimethacrylate, trimethylolpropane trimethacrylate, ditrimethylol-propane tetraacrylate;and a peroxide-based free-radical initiator, wherein said copolymer of methyl methacrylate is present in an amount of 30-50 parts by weight dissolved in a solution of 65-85 parts by weight of monomeric methyl methacrylate and 3-15 parts by weight of the polyfunctional (meth)acrylate, especially

Abstract: The problem to be solved is to provide a dental gypsum powder capable of suppressing mixing of bubbles in a kneaded object while including a resin component. A dental gypsum powder includes 0.5 to 4 wt. % of a solid component included in acrylic polymer dispersion; and 0.001 to 0.2 wt. % of cyclic siloxane including 3 to 10 SiO(CH3)2 units. More preferably, it includes 1 to 3 wt. % of the solid component included in the acrylic polymer dispersion.

Abstract: Aspects of the invention include sunscreen formulations that include uniform, rigid, spherical nanoporous calcium phosphate particles. Also provided are methods of making the sunscreen formulations. The sunscreen formulations find use in sunblocking applications.

Abstract: A shaving oil wipe made from combining a wipe or wipe-type product with natural fats or oils for shaving. The shaving oil wipe includes a package unit and at least one shaving oil wipe received in the package unit. The shaving oil wipe includes a fibrous carrier and a shaving oil composed of oils from either natural or synthetic sources. The shaving oil is disposed on the surface of the fibrous carrier or impregnated on the fibrous carrier. When the shaving oil of the shaving oil wipe is applied on a user's skin, a layer of oil is produced on the skin to provide good lubrication for shaving. Convenience of usage, good portability, and efficient application of shaving oil to skin are advantages.

Abstract: An aqueous hair leave-on composition directed to an aqueous hair leave-on composition for hair frizz reduction comprising from about 0.15% to about 12.0% of a moisture control material or mixture of moisture control materials wherein the moisture control material is selected from one or more of the following class: 1) Class II having the structure selected from: wherein R is hydrogen or metal ion, R6 is methyl, ethyl, propyl, alkenyl or phenyl having less than 12 carbon atoms and wherein R7, R8, R9, R10, R11, R12 are hydrogen, methyl, ethyl, propyl, phenyl, hydroxyl, methoxy or ethoxy groups; an alcohol wherein R13 is an alkyl, alkenyl, straight or branched carbon chains and; and wherein R14 is hydrogen, hydroxyl, alkyl, methyl, ethyl and propyl wherein the structure of such alcohol contains less than 20 total carbon atoms; c) alcohol comprising an unsaturated double bond in the C2 position.

Abstract: An oil-in-water emulsion including, by 100% of its mass: 60% to 98% of aqueous phase (A1), including 0.05% to 1.65% of a cross-linked anionic polyelectrolyte (P) resulting from the polymerisation, in the presence of at least one cross-linking agent, of partially or completely salified 2-methyl-2-[(1-oxo-2-propenyl)-amino]-1-propanesulphonic acid with at least one neutral monomer selected from N,N-dialkyl acrylamides, wherein each alkyl group has between one and four carbon atoms, and at least one monomer of formula (I): R=radical C8-C20 and 1?n?20; 2% to 40% of fatty phase (A2), including 1.25% to 50% of an emulsifying system (S) with at least one surfactant selected from alkylpolyglycoside compositions, alkylpolyglycoside and fatty alcohol compositions, polyglycerol esters, alkoxylated polyglycerol esters, polyglycolpolyhydroxystearates, polyglycerol polyhydroxystearates, alkoxylated polyglycerol polyhydroxystearates, polyethylene glycol/alkyl glycol copolymers; 50% to 98.

Abstract: The instant invention relates to a colour changing composition in the form of an emulsion comprising, at least: a) microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least one emulsifying hydrophilic gelifying agent chosen from 2-acryl-amido-2-methylpropanesulphonic acid copolymers, and c) at least one C6-C10 aromatic ether of C2-C9 polyol.

Abstract: The instant invention relates to a colour changing composition in the form of an emulsion comprising, at least: a) microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least partially neutralized, crosslinked acrylic homopolymers or copolymers preferably in a non-particulate form.

Abstract: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.

Abstract: Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically relevant fragrances.

Abstract: Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically acceptable UV-filter substances.

Abstract: Disclosed are active ingredient combinations of alkylamidothiazoles and one or more cosmetically or dermatologically acceptable preservatives.

Abstract: A personal care composition is provided having a highly volatile fragrance which incorporates alpha pinene, beta pinene, hexyl acetate, limonene, (+)-citronellal, dihydromyrcenol, alpha citronellol, beta citronellol, genaniol, lilial or combinations thereof in conjunction with tricyclodecane amide. The tricyclodecane amide functions to prevent fast volatilization of the highly volatile fragrance components when the personal care composition is applied to skin or hair of the human body.

Abstract: The present invention provides compositions and methods for reducing skin pigmentation. The invention comprises inhibitors of sialyltransferase, inhibitors of oligosaccharide formation or oligosaccharide activity, and methods of using such inhibitors. In certain embodiments, the invention comprises inhibiting the formation and/or activity of Neu5Ac(?2,6)Gal/GalNAc-containing oligosaccharides.

Abstract: A problem of the present invention is to provide a skin collagen production-promoting agent without safety problems. Another problem of the present invention is to provide a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product containing such a substance. TGF-? and/or a TGF-? degradation product, which is acquired by degrading TGF-? with a protease such as pepsin, pancreatin, etc., are used as a skin collagen production-promoting agent or the active ingredient of a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product. The aforementioned TGF-? and/or TGF-? degradation product have an effect of increasing the collagen content of the skin.

Abstract: The present invention relates to a transparent sol, gel composition containing high concentrations of vitamin C and vitamin C derivative. More specifically, disclosed is a technical field associated with a vitamin C composition, which is usable as an essence, a mask pack, a hydrogel mask, or the like, by making a composition containing a high concentration of vitamin C or vitamin C derivative, a polyalcohol, an acid mucopolysaccharide, and a hydrophilic solvent, into a sol or gel so as to stabilize the high concentration of vitamin C or vitamin C derivative in an aqueous solution.

Abstract: The present invention is directed to the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, to increase nail growth rate. The invention is further directed to the use of chitosans to accelerate nail growth rate during treatment of nail illnesses, nail dystrophy or other nail conditions, in order to shorten considerably the specific treatments of said nail illnesses, nail dystrophy or other nail conditions.

Abstract: Sunscreen formulations with improved thickening and waterproofmg properties include a polymer prepared from monomers including: styrene, a (meth)acrylic acid-containing monomer and an ester of acrylic acid or methacrylic acid or an acryl amide monomer, and an acrylic acid homopolymer thickener.

Abstract: A conditioning and cleansing composition comprising at least one detersive surfactant, a silicone conditioning agent and a nonionic, amphiphilic polymer that mitigates the loss silicone deposition on keratinous substrates is disclosed. The nonionic, amphiphilic polymer is prepared by polymerizing a monomer composition comprising: a) from about 55 to about 95 wt. % of at least one vinyl amide monomer (based on the weight of the total monomers present); b) from about 5 to about 45 wt. % of at least one vinyl ester of an aliphatic carboxylic acid containing an acyl moiety having 2 to 22 carbon atoms (based on the weight of the total monomers present); c) from about 0 to about 1 wt. % of at least one polyunsaturated crosslinking monomer containing at least two polymerizable ethylenically unsaturated moieties (based on the total dry weight of the polymer); d) from about 0 to about 10 wt.

Abstract: Described herein are oral care compositions comprising a crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, together with particular co-polymers as additional excipients; including some embodiments which further comprise a calcium abrasive.

Abstract: Compositions comprising an organic sunscreen in combination with (i) nylon particles, (ii) silica particles, and (iii) barium sulfate particles provide an improvement in SPF as compared to an otherwise identical composition lacking any one of the three ingredients (i)-(iii). The compositions advantageously provide high diffuse transmittance, giving a natural look to the skin.

Abstract: A method for applying undiluted 100% Organic Virgin Coconut Oil to the eyelashes and/or eyebrows of a user via a brush is described. The brush employed is preferably equipped with a series of off-set bristles configured to be soft on the lashes, yet firm enough to adequately apply the coconut oil to the lashes and distribute the coconut oil evenly across all lashes. Via this method, the organic virgin coconut oil is applied to the lashes such to ensure that each lash or brow is effectively moisturized in order to enhance the life and aesthetic quality of the eye lashes and/or eyebrows.

Abstract: The present invention relates to processes for producing treated olive mill process water (OMPW). In some exemplary embodiments, the treated OMPW is used in the preparation/production of body care products.

Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to bacterial preparations of Lactobacillus plantarum NCC 2936 (CNCM I-4026). An aspect of the invention is a composition for use in improving oral health comprising a bacterial preparation of Lactobacillus plantarum NCC 2936.

Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.

Abstract: The pharmaceutical composition includes a drug layer comprising an active ingredient, a surfactant, an acidic component and an effervescent ingredient. The active ingredient comprises a nucleic acid, a peptide or a protein. The acidic component and effervescent ingredient of the drug layer are dissolved in the water to react for generating carbon dioxide and bubbles thereof. The surfactants surround the carbon dioxide gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure.

Abstract: An oxygenated saline composition is provided comprising stabilized oxygen, sodium chloride (aqueous saline solution), and optionally one or more homeopathic components. The stabilized oxygen can include quad-atomic oxygen. Also provided is a method for treating, reducing or preventing nasal and/or sinus congestion, allergy, dryness, throat irritation, skin irritation, wounds, or eye irritation comprising administering to an individual in need thereof an effective amount of an oxygenated saline composition comprising stabilized oxygen, aqueous saline solution, and optionally one or more homeopathic components, wherein the composition is administered by intranasal spraying, throat spray, skin spray, sublingually, or by eye drops.

Abstract: An ocular drug delivery system can include a composition in which a formulation including recombinant human growth hormone (rHGH) is contained in a polymer matrix. The composition is configured for placement in or on the eye of a subject, and provides controlled release of an amount of the rHGH to the eye effective to promote healing of a conjunctival, sclera and or corneal wound.

Abstract: The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions. The suspension formulations can include cyclosporin A and in some embodiments, Form 1 or Form 2 cyclosporin A. A delivery system can be provided that includes two parts, a first part containing particles of cyclosporin and a second part containing other components that can be combined with the first part to make a suspension formulation. The suspension can be injected into the subconjunctival or other periocular space to treat ocular conditions, such as dry eye disease.

Abstract: The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the xylitol in a slurry and (b) then shaping the extruded slurry and cooling the product to form a solid. The present invention additionally is directed to a product produced therefrom.

Abstract: This invention relates to a method for the preparation of sterile aqueous suspensions of ciclesonide by sterilization with moist heat. The invention further relates to pharmaceutical compositions in particular to sterile aqueous suspensions of ciclesonide for administration by nebulization in the prophylaxis and/or treatment of respiratory diseases.

Abstract: The present invention provides a nano/micro bubble system for drug delivery comprising a gas core, a plurality of surfactants and an active ingredient. The surfactants surround the gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure and comprises a nucleic acid, a peptide or a protein.

Abstract: The presently disclosed LDL nanocarrier is an effective and appropriate transporter for DHA in biological systems. The LDL-DHA nanoparticle was shown to be preferentially cytotoxic to malignant liver cells. LDL-DHA nanoparticles show great promise as an anti-cancer agent.

Abstract: The present invention is anti-itching powder that blocks transmission to stratum corneum and invasion up to epidermal cells by emulsion as a result of further concentration on skin stratum corneum. The emulsion is produced by mixing sweat continuously secreted during rest and sebum. The emulsion becomes a cell disorder composition. Specifically, the anti-itching powder as a fine powder contains main ingredients of aluminum chloride or alum and cyclodextrin. A fine powder as a base is dispersed into and combined with the fine powder. The application of the fine powder over the skin prevents sudden itch without blocking emission and transpiration of moisture in the sweat from the skin stratum corneum.

Abstract: The invention relates to stable pharmaceutical compositions comprising a glucokinase (GK) activator suitable for oral administration. The invention also relates to methods of making and using such pharmaceutical compositions.

Abstract: The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

Abstract: Microspheres comprising a core material, wherein the microspheres have a circularity greater than 0.95 and an aspect ratio greater than 0.95, and methods of manufacturing the same. The microspheres may be useful in the manufacture of sustained and modified release active pharmaceutical ingredient (API) microspheres, as a free flowing excipient for mini-tablets and in the manufacture of API dispersions.

Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 0.1 to 7 milligrams mannitol.

Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising a pharmaceutically active amphetamine salt covered with an immediate-release coating and a pharmaceutically active amphetamine salt covered with an enteric coating wherein the immediate release coating and the enteric coating provide for multiple pulsed dose delivery of the pharmaceutically active amphetamine salt. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.

Abstract: The present invention relates to solid pharmaceutical compositions comprising the phosphatidylinositol 3-kinase inhibitor compound 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine or a pharmaceutically acceptable salt thereof, sodium stearyl fumarate, and optionally at least one additional pharmaceutically acceptable carrier. The present invention also relates to the processes for their preparation and to their use as medicaments for the treatment of cancer.

Abstract: Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bite acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyric acid-? (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.

Abstract: There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.

Abstract: The present invention relates to a gastroretentive tablet for treating unresectable hepatocellular carcinoma, comprising an enteric polymer, a nanoparticle and an excipient, wherein the nanoparticle comprises an oral multikinase inhibitor, wherein the oral multikinase inhibitor is coated with an amino methacrylate copolymer, wherein the oral multikinase inhibitor is sorafenib, and wherein the enteric polymer is methacrylic acid copolymer. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof.

Abstract: The present disclosure relates to a new, stable, oil based liquid suspension filled hard capsule dosage form for bismuth salts such as bismuth subsalicylate, a process for its manufacture, methods to deliver bismuth salts to humans or animals via stable hard capsules, and improved methods of treating gastrointestinal disorders with such dosage forms.

Abstract: An ingestible pill includes a coating configured to dissolve in a small intestine; a core, which includes a medication-delivery element, which (a) has a compressed shape when disposed within the coating, and (b) is configured to assume, after the coating dissolves, an expanded shape; a medication; and a mucoadhesive. When unconstrained in the expanded shape, the medication-delivery element (a) is shaped so as to define first and second surfaces on opposite sides of the medication-delivery element, which have respective outer perimeters, which surround respective spaces of the respective surfaces, which spaces have respective greatest dimensions equal to between 2 and 10 cm, and each of which spaces has an area equal to at least 50% of the square of the greatest dimension; and (b) has an average thickness between the first and the second surfaces of less than 6 mm. Each of the medication and the mucoadhesive at least partially coats the first surface.

Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.